COVID-19 preclinical drug development database
Targeting intracellular vesicular trafficking using a novel V-ATPase inhibitor to ameliorate pathogenicity of SARS-CoV-2 and related viral pathogens
King's College London
Added 08/07/2020 | Updated 04/10/2021
Project Details
Type of project
- Tier 2: testing existing molecules
- Tier 3: discovering and categorising new molecules
- Target identification or validation
Therapeutic target
- Preventing infection (prophylaxis or preventing cell entry)
- Preventing virus replication in early disease
- Preventing cytokine release syndrome (immunomodulation or suppression)
Type of supporting technology
Phase of project
- Lead optimisation and activity validation
- proof of concept study to validate target of new compound
Modality (if can be disclosed)*
- Small molecule
Molecular/cellular target (if known or can be disclosed)*
- V-ATPase
Partner institutions/organisations
- King's College London
Key contact
Name: Agamemnon E Grigoriadis
Email Address: agi.grigoriadis@kcl.ac.uk
Phone Number: 020-7188-1807
Key Collaborators:
Prof Agamemnon Grigoriadis
Prof Paul Long
Prof Michael Malim
Anticipated timeframe of future outputs
3-6 months
Similar Projects
Project Name
Lead institution
